-
Article
Open AccessDecoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence
The use of sodium-glucose co-transporter 2 inhibitors to treat heart failure with preserved ejection fraction (HFpEF) is under investigation in ongoing clinical trials, but the exact mechanism of action is unc...
-
Article
Preload dependence of pulmonary haemodynamics and right ventricular performance
Systolic pulmonary artery pressure (SPAP) and right heart adaptation in relation to pre-existing preload are often disregarded. To determine volume-related changes in the pulmonary-right ventricle (RV) unit an...
-
Article
Open AccessMortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018
To assess mortality trends at 1 and 3 years from 2001 to 2018 in a real-life cohort of HF outpatients from different etiologies with depressed and preserved LVEF. A total of 2368 consecutive patients with HF (...
-
Article
Open AccessLong-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline
Left ventricular ejection fraction (LVEF) trajectories and functional recovery with current heart failure (HF) management is increasingly recognized. Type 2 diabetes mellitus (T2D) leads to a worse prognosis i...